• Human Vaccines, Blood Plasma Products and Veterinary Vaccines
• Increase sales and income in H2 due to seasonal cycle of influenza vaccine, mainstay product
• Consolidated in Q2
• Boost consolidated operating income up JPY 3.0 billion in FYE March 2019
• Supplying 20 single-supply products* in Japan
• Have production capacity of pandemic influenza vaccines for 57 million people, half of Japanese population
* Single-supply products: Drugs only one pharmaceutical company manufactures in Japan. No alternative is available.
• Restore reliability – GMP violation
• Accelerate research and development for future growth
• Human Vaccines, Blood Plasma Products and Veterinary Vaccines
• Increase sales and income in H2 due to seasonal cycle of influenza vaccine, mainstay product
• Consolidated in Q2
Estimating net sales JPY 30.0 billion and operating income JPY 3.5 billion (non-consolidated) in FYE March 2019• Boost consolidated operating income up JPY 3.0 billion in FYE March 2019
Social responsibility• Supplying 20 single-supply products* in Japan
• Have production capacity of pandemic influenza vaccines for 57 million people, half of Japanese population
* Single-supply products: Drugs only one pharmaceutical company manufactures in Japan. No alternative is available.
Issues to be addressed• Restore reliability – GMP violation
• Accelerate research and development for future growth